Cytek BioSciences, Inc. (CTKB) News
Filter CTKB News Items
CTKB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CTKB News From Around the Web
Below are the latest news stories about Cytek Biosciences Inc that investors may wish to consider to help them evaluate CTKB as an investment opportunity.
Cytek Biosciences Non-GAAP EPS of $0.09 misses by $0.02, revenue of $127.95M beats by $2.53MCytek Biosciences press release (CTKB): FY Non-GAAP EPS of $0.09 misses by $0.02.Revenue of $127.95M (+37.8% Y/Y) beats by $2.53M. |
Cytek Biosciences, Inc.''s (CTKB) CEO Wenbin Jiang on Q4 2021 Results - Earnings Call TranscriptNo summary available. |
Cytek Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results2021 Revenue Increased 38% Compared to Prior Year |
Boeing And 3 Other Stocks Bought By InsidersUS stocks closed mixed on Wednesday following the release of minutes from the recent Federal Reserve meeting. Investors, meanwhile, focused on some notable insider trades. When insiders purchase shares, it indicates their confidence in the company''s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga''s insider transactions platform. Cytek Biosciences The Trade: Cytek Biosciences, Inc. (NASDAQ: CTKB ) Director Rajeev Shah acquired a total of 498,629 shares at an average price of... |
Cytek to Participate in the 42nd Annual Cowen Health Care ConferenceFREMONT, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating virtually in the upcoming 42 nd Annual Cowen Health Care Conference. |
Cytek Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022FREMONT, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23 rd , 2022. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook. |
Reilly Financial Advisors, Llc Buys Sony Group Corp, The Toronto-Dominion Bank, Carrier Global ...La Mesa, CA, based Investment company Reilly Financial Advisors, Llc (Current Portfolio) buys Sony Group Corp, The Toronto-Dominion Bank, Carrier Global Corp, Enbridge Inc, Oshkosh Corp, sells Telefonaktiebolaget L M Ericsson, HDFC Bank, EnerSys, Cytek Biosciences Inc, Dominion Energy Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Reilly Financial Advisors, Llc. |
Should Cytek Biosciences, Inc. (NASDAQ:CTKB) Focus On Improving This Fundamental Metric?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like... |
Cytek® Biosciences Expands Fremont Headquarters, Tripling Its Manufacturing CapacityOperations to Accommodate Increasing Demand for Cell Analysis SolutionsFREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that it has opened a new facility in Fremont, California – tripling its current manufacturing capacity in order to meet growing global demand for cell analysis solutions. In addition to the new Fremont location, Cytek has also opened new offices in Seattle, Washington, which are |
Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...New York, NY, based Investment company Orbimed Advisors Llc (Current Portfolio) buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, HCA Healthcare Inc, Erasca Inc, sells Prelude Therapeutics Inc, Aurinia Pharmaceuticals Inc, Ascendis Pharma A/S, Natera Inc, Anthem Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Orbimed Advisors Llc. |